Hospira Upped to Neutral - Analyst Blog
05 Janeiro 2012 - 9:15AM
Zacks
We recently upgraded our rating on Hospira,
Inc. (HSP) from Underperform to Neutral with a target
price of $33.00.
Hospira is facing continued manufacturing problems at its Rocky
Mountain facility, which accounts for approximately 25% of the
overall net sales. Slowdown in production at the Rocky Mountain
facility due to remediation efforts undertaken in response to the
FDA's warning letter received in April 2010, led to a shortfall in
sales in the third quarter of 2011. The manufacturing remediation
resulted in additional costs for quality control, lost sales,
inventory loss and lower service levels.
Rocky Mountain is currently operating at 60%–70% of the normal
level. Though the company is aggressively working to address the
problem areas, the timeliness of remediation is unclear.
Moreover, the Symbiq and Plum pump issues remain matters of
concern. The timing of resolution of the matters related to the
Symbiq/Plum pumps or the FDA warning Letter remain unclear.
However, we believe that the negatives associated with the quality
control issues have been priced into the stock.
We believe the company’s top and bottom-lines will rebound once
the ongoing manufacturing issues get resolved. We like the
long-term prospects of Hospira as a leader in the attractive
generic injectables space.
The Specialty Injectable Pharmaceuticals (SIP) segment is the
biggest contributor to the company’s top-line. Growth prospects
appear promising due to increased demand for core generic
injectable drugs. The segment was bolstered by new drug launches,
particularly the generic versions of oncology drugs like
Sanofi Aventis’ (SNY) Taxotere and Eli
Lilly’s (LLY) Gemzar.
Moreover, Hospira is fast working on expanding its biosimilar
portfolio. It already markets two biosimilars- Nivestim, a
biosimilar of Amgen’s (AMGN) Neupogen and
Retacrit, a biosimilar of Johnson and Johnson’s
(JNJ) Eprex.
Biosimilars are expected to be significant growth drivers for
the generics industry in 2015 and beyond. We believe the
biosimilars market represents a huge commercial opportunity with
more than $60 billion of biologic sales slated to lose patent
protection through 2017.
Further, Hospira also has a strong pipeline, which could boost
its top-line growth in the long term. As of September 30, 2011,
Hospira's generic pharmaceutical pipeline consisted of 73 products,
most of which are related to oncology and anti-infectives with the
remainder targeting cardiovascular, anesthesia and other areas.
Moreover, Hospira boasts of a strong biosimilars pipeline with 11
compounds in different stages of development.
These positive factors have caused us to upgrade the stock to
Neutral.
AMGEN INC (AMGN): Free Stock Analysis Report
HOSPIRA INC (HSP): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024